Barriers to access of precision guided therapies for children with high‐risk cancer
Pediatric Blood & Cancer · 2024-11 · 71 (11)
DOI: 10.1002/pbc.31147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 26.08.2024. Verfasst von Carolyn Mazariego und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Neoplasms, Precision Medicine, Health Services Accessibility. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Institute NSW, Translational Program, Zero Childhood Cancer National Personalised Medicine Program.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Accessing compassionate access schemes to obtain novel therapeutic agents for children with hard‐to‐treat cancers can be fraught with challenges such as regulatory barriers and limited resources. This study aimed to explore clinician perspectives on the barriers, impacts and ethical considerations of accessing novel therapeutic agents within the context of a paediatric oncology precision medicine trial.
Methods
We gathered data from 37 semi‐structured interviews with paediatric oncologists participating in the PRecISion Medicine for Children with Cancer (PRISM) study, a precision medicine clinical trial in Australia. The interviews, conducted over 2 years, focused on paediatric oncologist's experiences with the PRISM trial. Interviews were re‐analysed to identify themes related to access pathways and any challenges in obtaining novel agents through thematic analysis. The resulting thematic framework was discussed and refined by a multidisciplinary team.
Results
Three main themes were identified: (i) barriers to access, including poor drug availability, lack of evidence and the time burden of the application process; (ii) impacts of inaccessibility, encompassing medical consequences and financial burden on families; and (iii) ethical considerations, centred around balancing realistic expectations and providing compassionate care to patients and families. Paediatric oncologists expressed frustration with the complex regulatory landscape and the lack of systematic reporting on applications and outcomes of obtaining novel agents. Lengthy wait times for decision notifications were also highlighted, raising concerns about missed therapeutic opportunities for patients.
Conclusion
This study provides insight to the challenges faced when seeking access to novel therapies for paediatric oncology patients. There is a clear need for improved communication, streamlining processes and increased resources to facilitate access to novel agents. Further resource development is necessary to address these complexities in accessing novel therapy agents to ultimately ensure equitable and timely access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.
- Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, New South Wales, Australia.
- Behavioural Sciences Unit, Kids Cancer Centre, Sydney Children's Hospital, Sydney, New South Wales, Australia.
- Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.
- Children's Cancer Institute Australia, Lowy Cancer Research Centre, Sydney, New South Wales, Australia.
ORCID-Profile: Carolyn Mazariego, Rebecca Daly, Brittany McGill, Lauren Kelada, Kate Hetherington
Förderung
- Cancer Institute NSW
- Translational Program
- Zero Childhood Cancer National Personalised Medicine Program
- NHMRC of Australia
- Kids Cancer Foundation
- Luminesce Alliance-Innovation for Children's Health
Zitieren
APA
Mazariego, C., Daly, R., McGill, B., Kelada, L., McKay, S., Hetherington, K., Ziegler, D. S., Wakefield, C. E., & Taylor, N. (2024). Barriers to access of precision guided therapies for children with high‐risk cancer. Pediatric Blood & Cancer, 71(11). https://doi.org/10.1002/pbc.31147
Vancouver
Mazariego C, Daly R, McGill B, Kelada L, McKay S, Hetherington K, et al. Barriers to access of precision guided therapies for children with high‐risk cancer. Pediatric Blood & Cancer. 2024;71(11). doi:10.1002/pbc.31147
BibTeX
@article{Mazariego2024,
author = {Mazariego, Carolyn and Daly, Rebecca and McGill, Brittany and Kelada, Lauren and McKay, Skye and Hetherington, Kate and Ziegler, David S and Wakefield, Claire E and Taylor, Natalie},
title = {Barriers to access of precision guided therapies for children with high‐risk cancer},
journal = {Pediatric Blood & Cancer},
year = {2024},
volume = {71},
number = {11},
doi = {10.1002/pbc.31147}
}
EUVIMED